Article Text

PDF
Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study
  1. S Furukawa,
  2. S Yasuda,
  3. O Amengual,
  4. T Horita,
  5. T Atsumi,
  6. T Koike
  1. Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  1. Correspondence to:
    Dr S Furukawa
    sinfuru19680804{at}hotmail.com

Statistics from Altmetric.com

In patients with systemic sclerosis (SSc), endothelial cell activation or damage in small vessels is followed by intimal hyperplasia and peripheral ischaemia.1 Raised levels of plasma von Willebrand factor (vWF), thrombomodulin (TM), and other endothelial/thrombotic markers have been found in patients with SSc2–5; vWF is increased in plasma from patients with SSc with diffuse skin involvement and with severe disease, presumably correlating with disease activity.3 Besides a cholesterol lowering effect, statins exert non-lipid related mechanisms, so-called “pleiotropic effects”, which may contribute to reducing risks of cardiovascular events. In this study the effect of a low dose pravastatin on markers of endothelial cell activation/injury and coagulation was investigated in patients with SSc.

This clinical trial was approved by the ethical committee of Hokkaido University …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.